SARS-CoV-2 Spike-ACE2 Binding Assay Kit [RUO]
Each kit is sufficient for 96 tests and contains the following components:
1. One aluminum pouch with a Microwell plate (12 strips of 8 wells each) coated with SARS-CoV-2 S1RBD protein, sealed. The microwell strips can be used separately.
2. 10×Wash buffer-40 ml.
3. 5×Assay buffer-20 ml.
4. 100×Detection reagent: HRP-conjugated human ACE2, 0.12 ml.
5. 10x Positive control A (strong): An anti-S1RBD monoclonal antibody, 22 ul
6. 10x Positive control B (medium), An anti-S1RBD monoclonal antibody, 22 ul
7. Substrate solution, 12 ml, ready for use.
8. Stop solution, 12 ml, ready for use.
9. Blank control, 1 ml, ready for use
The ImmunoDiagnostics SARS-COV2 S1RBD-ACE2 Binding Assay is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect the neutralizing antibodies in human plasma or serum which inhibit the S1RBD-ACE2 interaction, and can also be used for screening the inhibitors and potential drugs and vaccine development.
This product is intended for research use only.
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). SARS-CoV-2 is an enveloped virus with a positive-sense RNA genome and a nucleocapsid of helical symmetry. The SARS-CoV-2 entry into host cells is mediated by the transmembrane spike (S) glycoprotein, which contains a receptor binding domain (RBD). S1RBD is responsible for binding with angiotensin converting enzyme-2 (ACE2), leading to endocytosis into the host cells and viral replication. S1RBD is the main target of neutralizing antibodies upon infection and the focus of the therapeutic drug and vaccine design. Molecules that inhibit formation of the S1RBD-ACE2 complex in vitro could be potential treatment for COVID-19 infection.
The SARS-COV2 S1RBD-ACE2 Binding Assay is competitive ELISA assay, which can mimic the virus neutralization process. 96-well plates are coated with SARS-CoV-2 S1RBD protein that captures neutralization antibodies or compounds which bind to SARS-CoV-2 S1RBD protein in the sample. After washing away unbound materials, captured neutralization antibodies or compounds can block the binding between horseradish peroxidase (HRP) conjugated recombinant human ACE2. After washing step, the chromogenic substrate 3,3’,5,5’-tetramethylbenzidine (TMB) is added. Color reaction is stopped by 2M H2SO4. The inhibitory efficiency of neutralization antibodies or compounds against SARS-CoV-2 S1RBD captured inside the wells is inversely proportional to the color density generated in the coupled oxidation-reduction reaction.
SAMPLE COLLECTION AND STORAGE INSTRUCTIONS
Handle serum or plasma sample in accordance with National Committee for Clinical Laboratory Standards guidelines for preventing transmission of blood-borne infection.
- Do not use grossly hemolyzed or lipemic samples.
- Serum: Use a blood separator tube and allow sample to clot for 30 minutes, then centrifuge for 10 minutes at 1000g. When the human serum is tested, the recommended dilution factor is 100-fold.
- Plasma: Treat blood with anticoagulant such as citrate, EDTA or heparin. Centrifuge for 10 minutes at 1000g within 30 minutes for plasma collection. When the human plasma is tested, the recommended dilution factor is 100-fold.
- Samples cannot be tested immediately should be aliquoted and must be stored frozen below -20°C. Avoid repeated freeze-thaw cycle.
- The dilution factor and concentrations of other testing samples (such as inhibitors and antibodies) should be determined by individual users.
- The kit should be stored at 2-8°C, and all reagents should be equilibrated to room temperature before use. Immediately after use remaining reagents should be returned to cold storage (2-8°C).
- Expiry of the kit and reagents is stand on labels.
- Once opened, the strips may be stored at 2-8°C for up to one month.